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Carcinomas of the head and neck represent the sixthmost common-
A homopolymer form of PA28γ interacts with both MDM2 and p53
proteins and facilitates their physical interaction, which promotes
ubiquitination- and MDM2-dependent proteasomal degradation of
p53, thus limiting its accumulation and resulting in inhibited apoptosis
after DNA damage. Elimination of endogenous PA28γ in human
cancer cells has been shown to abolish MDM2-mediated p53 degrada-
tion, increase the activity of p53, and enhance apoptosis (Zhang andly diagnosed type of cancer. Most of head and neck carcinomas are
histologically categorized as squamous cell carcinomas (SCC) (Chin
et al., 2006). SCC arises from squamous cells lining mucosal surfaces in
the nasal cavity, paranasal sinuses, nasopharynx, larynx, trachea, oral
cavity, oropharynx, salivary glands, and ears (Argiris et al., 2008).
The most common type of head and neck SCC is oral squamous cell car-
cinoma (OSCC), with an estimated annual incidence of 199 thousands of
cases and an estimated mortality of 98 thousands, only in men, as the
incidence of OSCC is much higher in men than in women (Bray et al.,
2012). The causative risk factors of OSCC include tobacco use and
alcohol consumption (Argiris et al., 2008).
A wide gamut of molecules is involved in oral carcinogenesis.
Aberrant expression of several genes is associated with hallmarks
of OSCC, including uncontrolled cell proliferation, defective apopto-
sis, loss of cell differentiation, epithelial–mesenchymal transition,
metastasis, and angiogenesis (da Silva et al., 2011). The potential of
such molecules as molecular biomarkers for diagnosis, prognosis
or monitoring of treatment efﬁcacy in OSCC has been intensively
investigated during the last decades. Immunohistochemical detec-
tion and/or mRNA expression proﬁling of promising molecular bio-
markers are expected to signiﬁcantly contribute to the generation
of novel screening tests with high sensitivity and speciﬁcity, as well
as tailor-made therapies against OSCC, in the era of personalized
medicine that has just emerged (Cheng et al., 2014). Besides that,
selective targeting of interactions between speciﬁc molecules that
are key players in cancer-related biochemical pathways could
dramatically impede oral carcinogenesis and therefore elongate or
ameliorate the survival of OSCC patients.
The proteasome activator 28 gamma (PA28γ) encodes the gamma
subunit of the 11S regulator of the immunoproteasome, a modiﬁed pro-
teasome that processes class I MHC peptides. PA28γ is a multifunctional
protein, implicated in the degradation of important cell cycle regulatorym.2015.07.004.
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.proteins in an ATP-independent manner. In fact, PA28γ inhibits apopto-
sis and promotes cell cycle progression (Rechsteiner and Hill, 2005)
Zhang, 2008).
In the E-Biomedicine, Jing Li and colleagues Li et al., 2015 assess
immunohistochemically PA28γ expression as a prognostic biomarker
in OSCC. For this purpose, a total of 368 patients from three independent
cohorts were included in the current study. Moreover, the authors used
an independent cohort of 460 patient specimens obtained between
1992 and 2013 in the TCGA database as an external validation cohort
to validate the prognostic value of PA28γ expression. Strong PA28γ
expression was shown to predict signiﬁcantly reduced disease-free
and overall survival in OSCC patients. More importantly, the unfavor-
able prognostic value of PA28γwas independent from other prognostic
factors such as smoking history, drinking history, cell differentiation
tumor stage, nodal stage, radiotherapy and chemotherapy.
Besides the prognostic signiﬁcance of PA28γ in OSCC, this study
provides evidence for the role of PA28γ in oral tumor growth and
metastasis. In more detail, PA28γ silencing in two OSCC cell lines
led to a decline in cell viability and colony growth. Moreover, growth
of tumor originating from OSCC cells transplanted subcutaneously
on the right back of BALB/c nude mice was much slower when
PA28γ was silenced in these tumor cells. The authors also showed
that PA28γ silencing suppresses tumor angiogenesis and increases
tumor cell apoptosis in xenograft models.
This study opens the door to assess the clinical value of PA28γ
expression as a surrogate prognostic biomarker in larger cohorts o
OSCC patients as well as to further investigate the role of PA28γ
overexpression in the pathobiology and progression of OSCC. The
clinical value of several molecules as putative diagnostic, prognostic
and treatment-response biomarkers in OSCC has been widely inves-
tigated during the last decades (Chawla et al., 2015; Ni et al., 2015)
The elucidation of the biochemical pathways implicated in oral carci-
nogenesis, tumor progression, and metastasis, taking also into
consideration the heterogeneity of oral tumors, would deﬁnitely
assist the discovery of novel candidate biomarkers in OSCC. Some
molecular biomarkers, including PA28γ, may also have prognostic
value in speciﬁc OSCC patient subgroups.
785C.K. Kontos / EBioMedicine 2 (2015) 784–785In conclusion, the dysregulation of PA28γ gene expression in OSCC
tissues compared to benign oral tumors, dysplasias, or normal specimens
originating from the oral cavity merits further investigation and
validation in independent and large cohorts of OSCC patients.
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